Abstract
Given the rates of pathological gambling and its impact on affected individuals and their relatives, effective treatments are needed. There are, however, no approved pharmacological treatments for pathological gambling. This paper describes the development of pharmacological treatments for pathological gambling and is based on a review of the literature published in the past 10 years. Important studies were carried-out on antidepressants, mood stabilizers, and antipsychotic agents. In the absence of comorbid psychiatric disorder, these studies did not conclude to the efficacy of these psychotropic drugs. A possible efficacy of opiate antagonist treatment for pathological gambling has been replicated in a number of placebo-controlled studies. Preliminary results on N-acetyl cysteine, Memantine and Topiramate produced significant improvement for pathological gamblers and may open new avenues for treatment.
Keywords: Pathological gambling, drugs, antidepressant, lithium, valproate, carbamazepine, naltrexone, nalmefene, topiramate, glutamate, N-acetylcysteine, gambling, antiepileptic, nefazodone, fluvoxamine, paroxetine, sertraline, cyclothymia, olanzapine
Current Pharmaceutical Design
Title: Psychopharmacological Treatment in Pathological Gambling: A Critical Review
Volume: 17 Issue: 14
Author(s): Sophia Achab and Yasser Khazaal
Affiliation:
Keywords: Pathological gambling, drugs, antidepressant, lithium, valproate, carbamazepine, naltrexone, nalmefene, topiramate, glutamate, N-acetylcysteine, gambling, antiepileptic, nefazodone, fluvoxamine, paroxetine, sertraline, cyclothymia, olanzapine
Abstract: Given the rates of pathological gambling and its impact on affected individuals and their relatives, effective treatments are needed. There are, however, no approved pharmacological treatments for pathological gambling. This paper describes the development of pharmacological treatments for pathological gambling and is based on a review of the literature published in the past 10 years. Important studies were carried-out on antidepressants, mood stabilizers, and antipsychotic agents. In the absence of comorbid psychiatric disorder, these studies did not conclude to the efficacy of these psychotropic drugs. A possible efficacy of opiate antagonist treatment for pathological gambling has been replicated in a number of placebo-controlled studies. Preliminary results on N-acetyl cysteine, Memantine and Topiramate produced significant improvement for pathological gamblers and may open new avenues for treatment.
Export Options
About this article
Cite this article as:
Achab Sophia and Khazaal Yasser, Psychopharmacological Treatment in Pathological Gambling: A Critical Review, Current Pharmaceutical Design 2011; 17 (14) . https://dx.doi.org/10.2174/138161211796150774
DOI https://dx.doi.org/10.2174/138161211796150774 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Editorial Board Member
Current Alzheimer Research Understanding the Binding Mechanism of Antagonist (AZD3293) Against BACE-1: Molecular Insights into Alzheimer’s Drug Discovery
Letters in Drug Design & Discovery Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis
CNS & Neurological Disorders - Drug Targets Nicotinamide and its Pharmacological Properties for Clinical Therapy
Drug Design Reviews - Online (Discontinued) Hippocampal Morphology and Autobiographic Memory in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Homocysteine Enhances Transmigration of Rat Monocytes through a Brain Capillary Endothelial Cell Monolayer via ICAM-1
Current Neurovascular Research Cardiovascular Risk in Patients with Primary Hyperparathyroidism
Current Pharmaceutical Design Phosphodiesterase as a New Therapeutic Target for the Treatment of Spinal Cord Injury and Neurodegenerative Diseases
Current Medicinal Chemistry A Role for Calcineurin in Alzheimers Disease
Current Neuropharmacology Recent Advances in Neuroinflammation Therapeutics: PPARs/LXR as Neuroinflammatory Modulators
Current Pharmaceutical Design In Vitro Models of the Blood-Brain Barrier: When to Use Which?
Current Medicinal Chemistry - Central Nervous System Agents Metal Ions and Metal Complexes in Alzheimer’s Disease
Current Pharmaceutical Design Herbal Medicines for Diabetes Management and its Secondary Complications
Current Diabetes Reviews On the Relationship Between the Light/Dark Cycle, Melatonin and Oxidative Stress
Current Pharmaceutical Design Editorial (Thematic issue: Soluble Beta Amyloid in a Continuum from Physiology to Pathology: Searching the Determinants of its Effects and Designing New Pharmacological Treatments)
Current Pharmaceutical Design Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets The Therapeutic Potential of Melatonin in Neurological Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) LC-MS/MS Determination of Bromperidol in Biological Matrices: Method Validation and Forensic Application
Current Pharmaceutical Analysis Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Subject Index To Volume 2
Current Hypertension Reviews